Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
04:22pm, Friday, 12'th Apr 2024
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link below NOVATO, Calif.
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
08:00am, Friday, 12'th Apr 2024
Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome Company will host investor call on April 17 at
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 22'nd Mar 2024
NOVATO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ra
Ultragenyx to Participate at Investor Conferences in March
04:30pm, Tuesday, 27'th Feb 2024
44 th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26 th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 202
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 23'rd Feb 2024
NOVATO, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
08:56am, Friday, 16'th Feb 2024
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
11:55pm, Thursday, 15'th Feb 2024
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics
07:01pm, Thursday, 15'th Feb 2024
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall S
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Thursday, 15'th Feb 2024
Ultragenyx (RARE) came out with a quarterly loss of $1.52 per share versus the Zacks Consensus Estimate of a loss of $1.65. This compares to loss of $2.16 per share a year ago.
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
04:01pm, Thursday, 15'th Feb 2024
2023 Total Revenue of $434 million, Crysvita® revenue of $328 million and Dojolvi® revenue of $71 million 2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita reven
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
04:00pm, Thursday, 08'th Feb 2024
NOVATO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Thursday, 08'th Feb 2024
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright
07:34pm, Tuesday, 09'th Jan 2024
Ultragenyx Pharmaceutical Inc. (RARE) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RARE's 50-day simple moving average broke out
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
01:32pm, Monday, 08'th Jan 2024
Ultragenyx (RARE) reports preliminary full-year 2023 revenues, along with business updates, and shares 2024 revenue guidance.
Ultragenyx (RARE) Posts Update From AS Study of GTX-102
09:47am, Thursday, 04'th Jan 2024
Ultragenyx (RARE) completes enrollment in the phase I/II study of GTX-102 for the treatment of pediatric patients with AS. Top-line data from the study is expected in the first half of 2024.
